Small cell lung cancer therapeutic - Omega therapeutics
Latest Information Update: 23 Jun 2023
At a glance
- Originator Omega Therapeutics
- Class Antineoplastics; RNA
- Mechanism of Action RNA replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Small cell lung cancer
Most Recent Events
- 21 Jun 2023 Early research in Small cell lung cancer in USA (IV) (Omega Therapeutics pipeline, June 2023)